TrialBlood2012

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Andrzej J Jakubowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.